Test tube with Corona virus name label is seen in this illustration taken on January 29, 2020. REUTERS/Dado Ruvic
TOKYO, Jan 31 (Reuters) – Japanese trading and pharmaceuticals company Kowa Co Ltd (7807.T) on Monday said that anti-parasite drug ivermectin showed an "antiviral effect" against Omicron and other coronavirus variants in joint non-clinical research.
The company, which has been working with Tokyo's Kitasato University on testing the drug as a potential treatment for COVID-19, did not provide further details. The original Reuters story misstated that ivermectin was "effective" against Omicron in Phase III clinical trials, which are conducted in humans.
Clinical trials are ongoing, but promotion of ivermectin as a COVID-19 treatment has generated controversy.
Prominent vaccine sceptic Joe Rogan, whose podcast on Spotify has prompted protests by singers Joni Mitchell and Neil Young, has long stirred controversy with his views on the pandemic, government mandates and COVID-19 vaccines.
Rogan has questioned the need for vaccines and said he used ivermectin.
The drug is not approved for treatment of COVID-19 in Japan, and the U.S. Food & Drug Administration, the World Health Organization, the EU drug regulator and Merck (MRK.N), which makes the drug, have warned against its use because of a lack of scientific evidence that it has therapeutic effect. read more
In guidance on its website dated September 2021, the FDA noted growing interest in the drug for preventing or treating COVID-19 in humans but said it had received multiple reports of patients who had required medical attention, including hospitalisation, after self-medicating with it.
The use of ivermectin to treat COVID-19 is currently being investigated in a UK trial run by the University of Oxford. The researchers said on Monday that it was still under way and they did not want to comment further until they have results to report. read more
Many potential COVID-19 treatments that showed promise in test tubes, including the antimalarial hydroxychloroquine promoted by former U.S. President Donald Trump, ultimately failed to show benefit for COVID-19 patients once studied in clinical trials.
Our Standards: The Thomson Reuters Trust Principles.
Keep up with the latest medical breakthroughs, healthcare trends, pharmaceutical news and more.
Subscribe to our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved

source